Gilead Sciences, Inc.

Gilead Pharmasset LLC

Korea Research Institute of Chemical Technology

Novartis Vaccines & Diagnostics, Gmbh

Lilac Therapeutics, Inc.

Hongyan Guo

Michael L Mitchell

Lianhong Xu

Hyung-Jung Pyun

John O Link

James G Taylor

Hongtao Liu

Hong Yang

Randall Halcomb

Choung U Kim

Manoj C Desai

Scott D Schroeder

Thorsten A Kirschberg

Randall W Vivian

Elizabeth M Bacon

Darryl Kato

Jay P Parrish

Jianyu Sun

Richard L Mackman

William John Watkins

Lan Jiang

Jeromy J Cottell

Scott E Lazerwith

Jennifer R Zhang

Eda Y Canales

Michael Graupe

Chandrasekar Venkataramani

Aesop Cho

Zheng-Yu Yang

Barton W Phillips

Winston C Tse

Jiayao Li

Qiaoyin Wu

Ana Zurisadai Gonzalez Buenrostro

Qi Liu

Ryan McFadden

Kerim Babaoglu

Devan Naduthambi

Paul A Roethle

Nathan D Shapiro

Weibo Wang

Gediminas J Brizgys

Richard Y Huang

Michael O'Neil Hanrahan Clarke

Yi Xia

Haolun Jin

Samuel E Metobo

Michael R Mish

Xiaochun Han

James D Trenkle

Evan S Krygowski

Hang Chu

Joseph H Saugier

Gregg M Schwarzwalder

Devleena M Shivakumar

David W Lin

Anna E Hurtley

Suzanne M Szewczyk

Ill Young Lee

Jong Chan Son

Matthew J Von Bargen

John Edward Knox, Jr

Annette Olga Walter

Paul Hrvatin

Kyla Bjornson

Yingmei Qi

Gregg M Schwarzwälder

Zachary E R Newby

Amy S Lee

Xiaowu Chen

Steven S Pfeiffer

Mingzhe Ji

Rustum S Boyce

Zhenhong R Cai

Chien-Hung Chou

Terry Kellar

Kris Mendenhall

Eric Lansdon

Manuel Munoz

Rustum Boyce

Jamie Geier Bates

Elizabeth Bacon

Randall L Halcomb

Stacey Heumann

Ting Wang

Jake Cha

Gerry Rhodes

Hyung-Jun Pyun

Brian J Kirby

Kris G Mendenhull

Yurong Lai

Adam D Zajdlik

Amy Lee

James Taylor

Paul Roethle

Hongtae Liu

Thorstens A Kirschberg

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and uses thereof

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Substituted pyridotriazine compounds and uses thereof

The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Heterocyclic carboxylate compounds as glycolate oxidase inhibitors

The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Thienopyrimidine derivatives as ACC inhibitors and uses thereof

Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

Therapeutic compounds

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Antiviral compounds

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I). 

2-quinolinyl-acetic acid derivatives as HIV antiviral compounds

The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

Naphthalene acetic acid derivatives against HIV infection

Growing community of inventors

San Mateo, CA, United States of America

Hongyan Guo